Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announced today that Peter Jensen, Non-Executive Chairman, has purchased 30,000 ordinary shares of 0.1 pence each in the capital of the Company at a price of 36 pence per Ordinary Share. Following the transaction, the total beneficial interest of Peter Jensen is 300,000 Ordinary Shares, representing 0.05% of the of the issued share capital of the Company to which voting rights are attached.
Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
